Category News

Byondis Names Christoph Korpus, PhD, MBA as Chief Executive Officer, Expanding Multimedia Integration

Byondis Names Christoph Korpus, PhD, MBA as Chief Executive Officer, Strengthening Leadership with Multimedia Announcement Byondis B.V., an independent biotechnology company focused on the development of innovative targeted therapies for cancer, has announced a significant leadership transition with the appointment…

Read MoreByondis Names Christoph Korpus, PhD, MBA as Chief Executive Officer, Expanding Multimedia Integration

Cosette Pharmaceuticals Expands Branded Portfolio with SYMPAZAN® and Other Asset Acquisition from Assertio

Cosette Pharmaceuticals Broadens Branded Portfolio with Acquisition of SYMPAZAN® and Additional Assets from Assertio Cosette Pharmaceuticals has announced the successful closing of a strategic acquisition that significantly expands its branded product portfolio and reinforces its position in key therapeutic areas.…

Read MoreCosette Pharmaceuticals Expands Branded Portfolio with SYMPAZAN® and Other Asset Acquisition from Assertio

Humana Inc. and CPESN USA Launch Value-Based Pharmacist Rewards Program to Enhance Chronic Care

Humana Inc. Healthy Horizons in Ohio and CPESN USA Introduce Value-Based Pharmacist Quality Rewards Program to Improve Chronic Disease Care Humana Inc., through its Medicaid plan Humana Healthy Horizons in Ohio, has announced an expanded collaboration with CPESN USA aimed…

Read MoreHumana Inc. and CPESN USA Launch Value-Based Pharmacist Rewards Program to Enhance Chronic Care

Cognito Therapeutics Partners with Initiative to Replace “Dementia” Terminology Across Communications

Cognito Therapeutics Collaborates with Initiative to Replace the “D-Word,” Committing to Remove “Dementia” from All Communications Cognito Therapeutics, a late clinical-stage neurotechnology company focused on developing non-invasive therapies for neurodegenerative diseases, has announced a new partnership with the Initiative to…

Read MoreCognito Therapeutics Partners with Initiative to Replace “Dementia” Terminology Across Communications

Acadia Pharmaceuticals Announces Broad U.S. Availability of DAYBUE STIX for the Treatment of Rett Syndrome

Acadia Pharmaceuticals Expands U.S. Access to DAYBUE STIX for Patients with Rett Syndrome Acadia Pharmaceuticals has announced that DAYBUE® STIX (trofinetide) for oral solution—a newly developed powder formulation of its Rett syndrome therapy—is now broadly available across the United States.…

Read MoreAcadia Pharmaceuticals Announces Broad U.S. Availability of DAYBUE STIX for the Treatment of Rett Syndrome

Affinia Therapeutics Secures Health Canada Approval to Launch Phase 1/2 UPBEAT Trial of AFTX-201 in BAG3-Related DCM

Affinia Therapeutics Secures Health Canada Clearance to Launch UPBEAT© Phase 1/2 Trial Evaluating AFTX-201 for BAG3-Related Dilated Cardiomyopathy Affinia Therapeutics, a clinical-stage biotechnology company focused on advancing next-generation gene therapies for serious cardiovascular diseases, has announced a key regulatory milestone…

Read MoreAffinia Therapeutics Secures Health Canada Approval to Launch Phase 1/2 UPBEAT Trial of AFTX-201 in BAG3-Related DCM